

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

This announcement is not, and does not form any part of, an offer or invitation for the sale of securities in the United States (as defined in Regulation S under the Securities Act. Neither this announcement nor anything herein nor any copy thereof may be taken into or distributed, directly or indirectly, in or into the United States or any other jurisdiction where such release or distribution might be unlawful. The securities referred to herein have not been and will not be registered under the Securities Act, and may not be offered, sold or otherwise transferred within the United States unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The Company does not intend to register any securities described herein in the United States or to make any public offering of the securities in the United States.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

**COMPLETION OF PLACING OF NEW H SHARES
UNDER SPECIFIC MANDATE**

Placing Agents

Morgan Stanley



**Goldman
Sachs**

J.P.Morgan

Reference is made to the announcement of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated July 29, 2020 in relation to the placing of the Placing Shares to be issued under the Specific Mandate (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

COMPLETION OF THE PLACING

The Board is pleased to announce that all the Conditions have been satisfied and the Completion took place on August 5, 2020. An aggregate of 68,205,400 Placing Shares have been successfully placed by the Placing Agents to no less than six independent Placees at the Placing Price of HK\$108.0 per Placing Share pursuant to the terms and conditions of the Placing Agreement. To the best of the knowledge, information and belief of the Directors, having made all reasonable enquiries, the Placees, together with their respective ultimate beneficial owners, are third parties independent of, and not connected with, the Company and the connected persons of the Company.

The net proceeds from the Placing are approximately HK\$7.29 billion, and will be utilized in the following manner:

- (a) approximately 35.0% will be used for mergers and acquisitions including, but not limited to, expansion of the Group's presence in the US, Europe and Asia Pacific;
- (b) approximately 20.0% will be used for expansion of the Group's overseas operation;
- (c) approximately 15.0% will be used for construction of Changshu R&D Integrated Project;
- (d) approximately 10.0% will be used for repaying bank loans and other borrowings, the details of which are disclosed under the paragraph headed "Reasons for the Proposed Issuance of H Shares — (v) Optimization of financing structure" in the Circular; and
- (e) the remainder shall be used to replenish the working capital of the Company.

The Placing Shares are issued under the Specific Mandate granted to the Directors by the Shareholders at the AGM and class meetings of the Company held on May 15, 2020 to issue up to 95,487,500 H Shares. Immediately prior to the Placing, no H Shares have been issued by the Company pursuant to the Specific Mandate. Following the Completion, the Company has utilized approximately 71.43% of the Specific Mandate.

EFFECT ON SHAREHOLDING STRUCTURE OF THE COMPANY

The shareholding structure of the Company (i) immediately prior to the Completion; and (ii) as at the date of this announcement are set out below.

Shareholder	Class of Shares	Immediately prior to the Completion		As at the date of this announcement	
		Number of Shares	Approximate percentage of the total issued share capital (%)	Number of Shares	Approximate percentage of the total issued share capital (%)
The Founding Individuals	A	633,784,587	27.42%	633,784,587	26.63%
Sub total		633,784,587	27.42%	633,784,587	26.63%
The Places	H	—	—	68,205,400	2.87%
Other Public Shareholders	A	1,439,073,572	62.26%	1,439,073,572	60.47%
	H	238,718,984	10.33%	238,718,984	10.03%
Sub total		1,677,792,556	72.58%	1,745,997,956	73.37%
Total		<u>2,311,577,143</u>	<u>100.00%</u>	<u>2,379,782,543</u>	<u>100.00%</u>

Note:

The approximate percentages of the total issued share capital are rounded to the nearest two decimal places and may not add up to 100% due to rounding.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, August 5, 2020

As of the date of this announcement, the Board comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* For identification purposes only